Target intelligence / Profile preview

Major feline allergen 1 (Fel d 1) (Fel d 1)

Target
Fel d 1
Molecular classification
Secretoglobin, Protein
01

Overview

Major feline allergen 1 (Fel d 1) is a secretoglobin protein and the primary driver of cat-induced allergic reactions in humans, affecting up to 20% of the global population (PMID: 30102319). It is synthesized primarily in the salivary, sebaceous, and perianal glands of domestic cats (Felis catus) and is spread onto the fur during grooming, eventually becoming airborne on dander (PMID: 31289163). Structurally, Fel d 1 is a 35 kDa tetrameric glycoprotein consisting of two non-covalently linked heterodimers, each composed of two disulfide-linked chains (Chain 1 and Chain 2) (UniProt P30438). In sensitized individuals, Fel d 1 cross-links IgE antibodies on the surface of mast cells and basophils, triggering the release of histamine and other inflammatory mediators that cause allergic rhinitis and asthma (PMID: 32654147). Therapeutic strategies targeting Fel d 1 include human monoclonal antibodies designed to neutralize the allergen, feline vaccines that induce anti-Fel d 1 antibodies in the cat to reduce environmental shedding, and specialized cat food containing IgY antibodies to neutralize the protein in the cat's saliva.

Other names
Fel d IFeline domesticus allergen 1Secretoglobin family 1D member 1Secretoglobin family 1D member 2Feline allergen 1
02

Mechanism of action

Neutralization of the Fel d 1 protein to prevent its binding to IgE antibodies on mast cells and basophils, thereby inhibiting the allergic cascade. In feline-directed therapies, the mechanism involves reducing the amount of active Fel d 1 shed into the environment through vaccination or dietary neutralization.

03

Biological functions

Pheromone bindingLipid bindingImmunomodulation
04

Disease associations

Allergic rhinitisAsthmaAllergic conjunctivitisAtopic dermatitis
05

Safety considerations

Risk of anaphylaxis with allergen-specific immunotherapyUnknown physiological consequences of Fel d 1 suppression in catsPotential for reduced efficacy in patients with poly-sensitization
06

Interacting drugs

REGN1908

3 more in the full profile.

07

Biomarkers

Fel d 1-specific IgEFel d 1-specific IgG4Skin prick test reactivity

Beyond the preview

Go deeper on Major feline allergen 1 (Fel d 1) (Fel d 1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Major feline allergen 1 (Fel d 1) (Fel d 1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call